Greenwood Capital Associates’s OptimizeRx OPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-88,596
Closed -$431K 257
2024
Q4
$431K Buy
88,596
+21,240
+32% +$119K 0.06% 202
2024
Q3
$520K Buy
67,356
+4,999
+8% +$44.4K 0.07% 179
2024
Q2
$624K Buy
62,357
+8,455
+16% +$92.9K 0.08% 174
2024
Q1
$655K Sell
53,902
-773
-1% -$11.2K 0.09% 168
2023
Q4
$782K Buy
54,675
+20,245
+59% +$194K 0.1% 152
2023
Q3
$268K Sell
34,430
-14,036
-29% -$153K 0.04% 230
2023
Q2
$693K Buy
48,466
+666
+1% +$9.48K 0.1% 164
2023
Q1
$699K Sell
47,800
-921
-2% -$15.4K 0.1% 161
2022
Q4
$819K Buy
48,721
+1,376
+3% +$23.8K 0.13% 130
2022
Q3
$702K Buy
47,345
+14,111
+42% +$279K 0.12% 144
2022
Q2
$910K Buy
33,234
+3,838
+13% +$114K 0.15% 120
2022
Q1
$1.11M Buy
29,396
+3,172
+12% +$140K 0.29% 70
2021
Q4
$1.63M Buy
26,224
+1,362
+5% +$103K 0.23% 81
2021
Q3
$2.13M Sell
24,862
-234
-0.9% -$14.7K 0.33% 69
2021
Q2
$1.55M Buy
25,096
+740
+3% +$37.7K 0.23% 79
2021
Q1
$1.19M Sell
24,356
-1,604
-6% -$77.4K 0.19% 93
2020
Q4
$809K Buy
25,960
+6,635
+34% +$163K 0.14% 128
2020
Q3
$403K Buy
+19,325
New +$332K 0.08% 140

Other funds holding OPRX

Greenwood Capital Associates's OPRX Position: Q1 2025 in Review

Greenwood Capital Associates sold out of OptimizeRx (OPRX) in Q1 2025, closing a stake of 88,596 shares — an estimated $431K sold.

Greenwood Capital Associates first reported a position in OPRX in Q3 2020 and held it in 18 quarters. The position peaked at $2.13M in Q3 2021. 87 funds tracked by Wall St. Rank hold OPRX as of Q1 2025.

  • Greenwood Capital Associates reported no remaining OptimizeRx position as of Q1 2025 after selling out during the quarter.
  • Greenwood Capital Associates sold 88,596 OptimizeRx shares in Q1 2025, an estimated $431K.
  • Greenwood Capital Associates first reported a position in OptimizeRx in Q3 2020 and held it in 18 quarters.
  • Greenwood Capital Associates's OptimizeRx position peaked at $2.13M in Q3 2021.
  • 87 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2025.

Based on Greenwood Capital Associates's 13F filing for Q1 2025, filed 15 Apr 2025.